白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
Journal of Leukemia & Lymphoma
2015年
8期
449-452
,共4页
血液肿瘤%PD-1%CTLA-4%PD-L1%分子靶向治疗
血液腫瘤%PD-1%CTLA-4%PD-L1%分子靶嚮治療
혈액종류%PD-1%CTLA-4%PD-L1%분자파향치료
Hematological malignancies%PD-1%CTLA-4%PD-L1%Molecular targeted therapy
T细胞免疫功能缺陷导致多数血液肿瘤患者不能产生有效的抗肿瘤免疫应答,从而逃避宿主免疫系统的攻击,即肿瘤细胞免疫逃逸.近年来认为肿瘤免疫抑制最为重要的机制之一是CD8+T细胞的功能耗竭,主要为免疫细胞异常表达程序性死亡分子1(PD-1)和细胞毒性T淋巴细胞相关抗原(CTLA-4)等免疫抑制所介导,而阻断此通路可以使T细胞部分或全部恢复功能.文章介绍近年来血液肿瘤中PD-1和CTLA-4及二者在介导T细胞免疫耐受中的作用及其在靶向治疗研究中的进展,为血液肿瘤的免疫靶向治疗提供新的思路.
T細胞免疫功能缺陷導緻多數血液腫瘤患者不能產生有效的抗腫瘤免疫應答,從而逃避宿主免疫繫統的攻擊,即腫瘤細胞免疫逃逸.近年來認為腫瘤免疫抑製最為重要的機製之一是CD8+T細胞的功能耗竭,主要為免疫細胞異常錶達程序性死亡分子1(PD-1)和細胞毒性T淋巴細胞相關抗原(CTLA-4)等免疫抑製所介導,而阻斷此通路可以使T細胞部分或全部恢複功能.文章介紹近年來血液腫瘤中PD-1和CTLA-4及二者在介導T細胞免疫耐受中的作用及其在靶嚮治療研究中的進展,為血液腫瘤的免疫靶嚮治療提供新的思路.
T세포면역공능결함도치다수혈액종류환자불능산생유효적항종류면역응답,종이도피숙주면역계통적공격,즉종류세포면역도일.근년래인위종류면역억제최위중요적궤제지일시CD8+T세포적공능모갈,주요위면역세포이상표체정서성사망분자1(PD-1)화세포독성T림파세포상관항원(CTLA-4)등면역억제소개도,이조단차통로가이사T세포부분혹전부회복공능.문장개소근년래혈액종류중PD-1화CTLA-4급이자재개도T세포면역내수중적작용급기재파향치료연구중적진전,위혈액종류적면역파향치료제공신적사로.
T cell immune deficiency results in inefficient anti-tumor immune response in most patients with hematological malignancies,thereby tumor cells escaping the attack of host immune system,that is the immune escape of tumor cells.Recently,new insights regard to the CD8+ T cell exhaustion which is one of the most important mechanisms of tumor immune suppression.The CD8 + T cell exhaustion is mediated by abnormal expression of T-cell immunosuppressive receptors such as PD-1 and CTLA-4.Blocking these molecules may restore the partial or all functions of T cells.This article reviewed the advances on the role of the PD-1 and CTLA-4 in hematological malignancies,including their functions on mediating T cell-immune tolerance and the progression of targeted immunotherapy,to provide the new strategy for hematological malignancies.